Swedish Biotech Developing Stem Cell Therapies From Amniotic Fluid
Newly Listed Amniotics Will Target Niche Indications
Swedish biotech Amniotics is developing a broad pipeline of unique stem cell therapeutics based on technology that is broadly applicable to major disease markets which should eventually draw the attention of big pharma players, its CEO tells Scrip.
